Treatment of Newly Diagnosed POEMS Syndrome: Bortezomib or Lenalidomide? Experience from Two Countries
Mediterranean Journal of Hematology and Infectious Diseases, cilt.18, sa.1, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 1
- Basım Tarihi: 2026
- Doi Numarası: 10.4084/mjhid.2026.084
- Dergi Adı: Mediterranean Journal of Hematology and Infectious Diseases
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, Directory of Open Access Journals, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Anahtar Kelimeler: Bayesian analysis, Bortezomib, Lenalidomide, POEMS syndrome
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet
Özet
Background: POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes) syndrome is a rare plasma cell disorder where treatment selection remains largely empirical. Lenalidomide-based regimens are generally preferred in the first line due to concerns about bortezomib-induced neurotoxicity, despite limited comparative evidence. We aimed to directly compare the real-world efficacy and safety of first-line bortezomib-versus lenalidomide-based regimens. Methods: In this retrospective multicenter cohort, 26 newly diagnosed POEMS patients between 2005 and 2024 from Türkiye and Italy were included. Nine patients received bortezomib-based therapy and 17 received lenalidomide–dexamethasone. The primary endpoint was overall survival (OS); the secondary endpoint was hematologic response. Results: Bortezomib-based therapy achieved significantly higher rates of deep response (≥VGPR, defined as complete response or very good partial response) compared with lenalidomide (88.9% vs 37.5%; p = 0.013). Despite a higher prevalence of baseline symptomatic neuropathy in the bortezomib group (77.8% vs 29.4%; p = 0.038), no treatment-emergent worsening of neuropathy was observed. Model-based 5-year overall survival was 86.6% with bortezomib and 80.7% with lenalidomide (time ratio [TR] 0.61, 95% CrI 0.04–6.78), indicating no survival difference between the two strategies, with similar autologous transplantation rates and toxicity profiles. Conclusion: In this multicenter real-world cohort, bortezomib-based first-line therapy was associated with markedly deeper hematologic responses without excess neurotoxicity, and no survival difference could be demonstrated in this small cohort. These findings suggest that bortezomib-based therapy may be an effective upfront option in selected patients and support re-evaluating first-line strategies in prospective studies.